Bio-Rad Expects FY24 Non-GAAP Revenue To Decline 2.5-4% vs Prior Estimate Of Declining 1-2.5%
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories has revised its FY24 non-GAAP revenue forecast, now expecting a decline of 2.5-4%, compared to the previous estimate of a 1-2.5% decline.
August 01, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bio-Rad Laboratories has revised its FY24 non-GAAP revenue forecast, now expecting a decline of 2.5-4%, compared to the previous estimate of a 1-2.5% decline.
The downward revision in revenue forecast indicates potential challenges in Bio-Rad's business environment, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100